IDWeek 2023 Archives

Multiple HIV Research Achievements by Dr. Yaokai Chen’s Team from Chongqing Public Health Medical Center Was Selected for the 2023 IDWeek

By Mourabit Halima 2023.12.10

The IDWeek in the United States is one of the largest infectious disease academic conferences globally, often referred to as the "Oscars" of the infectious disease field. Numerous cutting-edge research findings would be shared and discussed at this highly anticipated academic event. During the recent 2023 IDWeek, Dr. Yaokai Chen's team from Chongqing Public Health Medical Center had four HIV-related research findings selected for the conference. One of these was presented as a Rapid-Fire Poster, while the other three were included in poster presentations.

IDWeek Interview | Dr. Shields: Real-World Study on the Efficacy of Two Generation BL-BLI Combination Therapy for MDR-PA

By Peter W. PENG 2023.11.30

Ceftolozane-tazobactam is a new BL-BLI combination drug, and ceftolozane is a third-generation cephalosporin antibiotic, and tazobactam is a beta-lactamase inhibitor. At the recent 2023 IDWeek in the United States, Dr. Ryan K. Shields from the University of Pittsburgh presented a real-world observational study assessing the effectiveness of ceftolozane-tazobactam compared to ceftazidime-avibactam in treating multidrug-resistant Pseudomonas aeruginosa (MDR-PA). He shared his insights in an interview with " Infectious Disease Frontline".

Can MRSA Surveillance Results Be Used to Discontinue Vancomycin for Infections Other Than Pneumonia?

By Peter W. PENG 2023.11.30

At the IDWeek 2023, Dr. Rebekah W. Moehring from the Duke Center for Antimicrobial Stewardship and Infection Control at Duke University presented a fascinating report on the use of MRSA surveillance in guiding empirical therapy for MRSA and de-escalation strategies to optimize vancomycin antibiotic management.

IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

By Peter W. PENG 2023.11.30

Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and vancomycin-resistant Enterococcus (VRE), exhibit high resistance and rapid transmission. Previous studies have established a close relationship between intestinal CRE colonization and infection, but the relationship between intestinal colonization and infection of other MDROs remains to be clarified. In a recent oral presentation at the 2023 Infectious Diseases Week (IDWeek 2023), a researcher reported a study on the relationship between MDRO intestinal colonization and the risk of bloodstream infection (BSI). Dr. Yonghong Xiao, from the First Affiliated Hospital, Zhejiang University School of Medicine, provides an introduction and commentary on this research.